Effect of low-dose baclofen administration on plasma insulin-like growth factor-I in persons with spinal cord injury

被引:13
作者
Bauman, WA
Kirshblum, SC
Morrison, NG
Cirnigliaro, CM
Zhang, RL
Spungen, AM
机构
[1] Vet Affairs Med Ctr, Spinal Cord Damage Res Ctr, Vet Affairs Rehabil Res & Dev Ctr Excellence, Bronx, NY 10468 USA
[2] Vet Affairs Med Ctr, Spinal Cord Damage Res Ctr, Bronx, NY USA
[3] Vet Affairs Med Ctr, Med Spinal Cord Injury & Res Serv, Bronx, NY USA
[4] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[5] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA
[6] Kessler Inst Rehabil, W Orange, NJ USA
[7] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA
关键词
gamma-aminobutyric acid; growth hormone; paraplegia;
D O I
10.1177/0091270006286641
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Patients with chronic spinal cord injury (SCI), a condition associated with reduced physical function, have been reported to have lower plasma insulin-like growth factor-I (IGF-I) levels than able-bodied persons. We evaluated the potential for daily low-dose baclofen administered over several weeks to increase plasma IGF-I levels. Ten healthy male outpatients with chronic SCI were Studied prospectively. Patients received escalating doses of boclofen for 4 weeks at each dose level (5, 10, and 20 mg/d). At each dose of baclofen, an increase in the plasma IGF-I was rioted; significant increases in plasma IGF-I occurred at 2 weeks after administration of drug at doses of 10 and 2 mg/d with a subsequent rise to peak levels on baclofen 20 mg/d [baseline, 205 +/- 74; peak, 218 +/- 76 (not significant), 239 +/- 83 (P <.05), 263 +/- 87 mu g/L (P < .05), at baclofen 5, 10, and 20 mg/d, respectively]. In conclusion, low-dose baclofen administration for 4 weeks stimulated the growth hormone-IGF-I axis in persons with SGI, with the potential for beneficial effects on body composition.
引用
收藏
页码:476 / 482
页数:7
相关论文
共 31 条
[1]
Ectopic expression of IGF-1 and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo [J].
Alzghoul, MB ;
Gerrard, D ;
Watkins, BA ;
Hannon, K .
FASEB JOURNAL, 2004, 18 (01) :221-223
[2]
BLUNTED GROWTH-HORMONE RESPONSE TO INTRAVENOUS ARGININE IN SUBJECTS WITH A SPINAL-CORD INJURY [J].
BAUMAN, WA ;
SPUNGEN, AM ;
FLANAGAN, S ;
ZHONG, YG ;
ALEXANDER, LR ;
TSITOURAS, PD .
HORMONE AND METABOLIC RESEARCH, 1994, 26 (03) :152-156
[3]
CHRONIC BACLOFEN THERAPY IMPROVES THE BLUNTED GROWTH-HORMONE RESPONSE TO INTRAVENOUS ARGININE IN SUBJECTS WITH SPINAL-CORD INJURY [J].
BAUMAN, WA ;
SPUNGEN, AM ;
ZHONG, YG ;
TSITOURAS, PD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (05) :1135-1138
[4]
BAUMAN WA, 1995, 77 ANN M END SOC WAS, P511
[5]
A SPECIFIC RADIOIMMUNOASSAY FOR THE GROWTH-HORMONE (GH)-DEPENDENT SOMATOMEDIN-BINDING PROTEIN - ITS USE FOR DIAGNOSIS OF GH DEFICIENCY [J].
BLUM, WF ;
RANKE, MB ;
KIETZMANN, K ;
GAUGGEL, E ;
ZEISEL, HJ ;
BIERICH, JR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (05) :1292-1298
[6]
HUMAN GROWTH-HORMONE AND HUMAN AGING [J].
CORPAS, E ;
HARMAN, SM ;
BLACKMAN, MR .
ENDOCRINE REVIEWS, 1993, 14 (01) :20-39
[7]
The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults [J].
Cuneo, RC ;
Judd, S ;
Wallace, JD ;
Perry-Keene, D ;
Burger, H ;
Lim-Tio, S ;
Strauss, B ;
Stockigt, J ;
Topliss, D ;
Alford, F ;
Hew, L ;
Bode, H ;
Conway, A ;
Handelsman, D ;
Dunn, S ;
Boyages, S ;
Cheung, NW ;
Hurley, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (01) :107-116
[8]
DAUGHADAY WH, 1989, PERSPECT BIOL MED, V32, P194
[9]
Growth hormone response to the GABA(B) agonist baclofen in major depressive disorder [J].
Davis, LL ;
Trivedi, M ;
Choate, A ;
Kramer, GL ;
Petty, F .
PSYCHONEUROENDOCRINOLOGY, 1997, 22 (03) :129-140
[10]
Growth hormone response to baclofen: A comparison of 10-mg and 20-mg doses in healthy men [J].
Davis, LL ;
Trivedi, M ;
Kramer, GL ;
Rush, AJ ;
Orsulak, PJ ;
Akers, L ;
Petty, F .
PSYCHIATRY RESEARCH, 1996, 60 (01) :41-47